Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Brunet, M.; Gelder, T. van; Asberg, A.; Haufroid, V.; Hesselink, D.A.; Langman, L.; ... ; Bergan, S. (2019)

Article / Letter to editor

• tacrolimus-personalized therapy
• pharmacokinetics
• biomarkers
• pharmacogenetics
• pharmacodynamics
• consensus
• immunologic biomarkers
• graft outcome
• graft injury
• tacrolimus target concentrations
• methods standardization
• new approaches in tacrolimus TDM
• PopPK/PG modeling

• All authors: Brunet, M.; Gelder, T. van; Asberg, A.; Haufroid, V.; Hesselink, D.A.; Langman, L.; Lemaitre, F.; Marquet, P.; Seger, C.; Shipkova, M.; Vinks, A.; Wallemacq, P.; Wieland, E.; Woillard, J.B.; Barten, M.J.; Budde, K.; Colom, H.; Dieterlen, M.T.; Elens, L.; Johnson-Davis, K.L.; Kunicki, P.K.; MacPhee, I.; Masuda, S.; Mathew, B.S.; Millan, O.; Mizuno, T.; Moes, D.J.A.R.; Monchaud, C.; Noceti, O.; Pawinski, T.; Picard, N.; Schaik, R. van; Sommerer, C.; Vethe, N.T.; Winter, B. de; Christians, U.; Bergan, S.
• Date: 2019-06-30
• Journal: Therapeutic Drug Monitoring
• Volume: 41
• Issue: 3
• Pages: 261 - 307
• DOI: doi:10.1097/FTD.0000000000000640